Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 1/Phase 2Diagnosis: Kidney CancerNCT ID: NCT01806064
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 13-170
Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose axitinib in patients with advanced renal cell carcinoma. Phase 2: To estimate the PFS of patients with advanced or metastatic RCC by RECIST 1.1 criteria in patients treated with axitinib and TRC105 compared to those treated with axitinib alone, following failure of one prior VEGF TKI
Conducting Institutions: Beth-Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital
Overall PI: Toni Choueiri, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators: David McDermott, MD,
Beth Israel Deaconess Medical CenterDror Michaelson, MD,
Massachusetts General Hospital
Contacts: Dana-Farber Cancer Institute:
Meghara Walsh, 617-632-5264,
firstname.lastname@example.orgDana-Farber Cancer Institute:
Amanda Fredericks, 617-632-5514,
email@example.comDana-Farber Cancer Institute:
Judith Prisby, 617-632-5068,
firstname.lastname@example.orgBeth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100